Friday, July 02, 2021 12:34:43 PM
A claim of the CEO lying may be slander and if he did it would be dumb but very had to prove. COVID issues were and are a main delay there too, IMO. Surely there was small chance of an AGN CSO or even the CRO to go to Australia and help expedite any issue. The money is already spent there and raising more does not make sense to me at this point. We assume the IPF/CC is still being attempted.
Right now Shareholders are disappointed with the IPF progress but most are waiting for FDA results, IMO. AGN and shareholders also needs patience. Some sold obviously and some bought back. That's trading the news.
The FDA will release the meeting results to the company around day 70. Idiopathic PF and COVID lung ALI seem related to me. Ifenprodil MOA/efficacy and safety of the drug in those situations of ALI is the target. IMO.
I bought back due to my faith and DD in Ifenprodil. I hope results will allow fair financing for a future CT for Low O2 patients (long-haulers?) from COVID and ALI. Without FDA support Ahh-shits.
AGN is not a Big Pharma and shareholders WONT easily be convinced to accept futher dilution to fix issues. Seems to me this small company is doing better than most/all of it's direct competition.
With good FDA support there is a fair possibility for a partner. A direct $2 buyout chance was Blown by inept Interim evaluations and presentation along with the current COVID decline, IMO. CM has said we will ride Ifenprodil if possible.
I hope they are investigating the recent Stroke data found for it too.
IL-6 effects on Tumors may also be a Phase 2+. IMO
Putting a marker down for DMT microdose enables that future and having support from Strassburg ect brings credibility there, IMO...GLTA...
*
PS, Australia... https://www.straitstimes.com/asia/australianz/half-of-australias-population-in-lockdown-as-delta-covid-19-variant-spreads
PS2
IF 'team cobra' was scamming or smart they would have had BLO buy the Yost/Breathalyzer through their control. Could have been an easy 'paper' deal. But Kal is a pretty strait, X Cop, IMO.
Your opinion has been well documented.
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM